The *Journal of Dermatological Science* publishes high quality peer-reviewed manuscripts covering the entire scope of dermatology, from molecular studies to clinical investigations. Laboratory and clinical studies which provide new information will be reviewed expeditiously and published in a timely manner.

The Editor and his Editorial Board especially encourage the publication of research based on a process of bilateral feedback between the clinic and the laboratory, in which incompletely understood clinical phenomena are examined in the laboratory and the knowledge thus acquired is directly reapplied in the clinic. This continuous feedback will refine and expand our understanding of both clinical and scientific domains.

Although the *Journal* is the official organ of the Japanese Society for Investigative Dermatology, it serves as an international forum for the work of all dermatological scientists. With an internationally renowned Editorial Board, the *Journal* maintains high scientific standards in the evaluation and publication of manuscripts. The *Journal* also publishes invited reviews, commentaries, meeting announcements and book reviews. Letters to the Editor reporting new results or even negative scientific data, if they contribute to advances in dermatology are encouraged. Letters to the Editor should be less than 1000 words with up to 2 figures or tables.

For more information, please check the homepage of the Japanese Society for Investigative Dermatology.

For membership information please contact:

Shigetoshi Sano, MD, PhD
Editor-in-Chief
4-23-406 Hagoromo cho, Nishinomiya, Hyogo, Japan 662-0051
e-mail: jds@jsid.org

**AUDIENCE**

Basic and Clinical Researchers in the field of Dermatology.
IMPACT FACTOR

2022: 4.600 © Clarivate Analytics Journal Citation Reports 2023

ABSTRACTING AND INDEXING

Science Citation Index
Web of Science
Embase
BIOSIS Citation Index
PubMed/Medline
Abstracts on Hygiene and Communicable Diseases
Elsevier BIOBASE
Biological Abstracts
BIOSIS Previews
Chemical Abstracts
Current Awareness in Biological Sciences
Current Contents
Embase
Index Veterinarius
Inpharma Weekly
Medical and Surgical Dermatology
PharmacoEconomics and Outcomes News
Protozoological Abstracts
Reactions Weekly
Review of Medical and Veterinary Entomology
Review of Aromatic and Medicinal Plants
Review of Medical and Veterinary Mycology
Sugar Industry Abstracts
Veterinary Bulletin
Wheat, Barley and Triticale Abstracts
Abstracts of Mycology
Horticultural Science Abstracts
Review of Agricultural Entomology
CABI Information
Cancerlit
Global Health
Inside Conferences
ISI Science Citation Index
MANTIS
Social SciSearch
TOXFILE
BIOSIS Toxicology
SIIC Data Bases
Elsevier BIOBASE
Current Contents - Clinical Medicine
Scopus

EDITORIAL BOARD

Editor-in-Chief
Shigetoshi Sano, Kochi Medical School, Department of Dermatology, Kochi, Japan

Past Editors-in-Chief
Hideoki Ogawa, Bunkyo-Ku, Japan
(1990 - 1992)
Kunihiko Yoshikawa, Osaka, Japan
(1993 - 1997)
Yoshiki Miyachi, Kyoto, Japan
Section Editors

Yoshiihide Asano, Tohoku University, Sendai, Japan
Collagen disease (especially scleroderma), Fibrosis, Vasculopathy, Autoimmunity

Curdin Conrad, University of Lausanne, Lausanne, Switzerland
Chronic inflammatory skin diseases, with a focus on psoriasis, rosacea, etc., Targeted therapies and their side effects, including targeted synthetic DMARDS (such as JAK inhibitors, TYK2), Innate and adaptive immunity, focusing on pDCs, T cell subsets, and signature pathways (Th1, Th2, Th17)

Hironobu Fujiwara, Laboratory for Tissue Microenvironment, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
Stem cell, Development, Regeneration, Extracellular matrix, Skin

Nikolas Haass, University of Queensland, Brisbane, Australia
Melanoma, Cancer Cell Biology, Targeted Therapy, Immune Therapy, Signalling Pathways, 3D Cell Culture, , Real-time Imaging

Tetsuya Honda, Hamamatsu University School of Medicine, Hamamatsu, Japan
Immunology, Inflammation, Atopic dermatitis, Psoriasis

Thomas Hornyak, University of Maryland Baltimore, Baltimore, United States of America
Immunology, Inflammation, Atopic dermatitis, Psoriasis

Ohsang Kwon, Seoul National University, Gwanak-gu, South Korea
Hair biology, Stem cell research, Wound healing, Regenerative medicine

Cheng-Che E. Lan, Kaohsiung Medical University, Kaohsiung, Taiwan
Photomedicine, Pigmentary disorders, Wound healing

Sei-ichiro Motegi, Gunma University, Maebashi, Japan
Systemic sclerosis, Skin fibrosis, Wound healing, Mesenchymal stem cells, Pressure ulcer, Angiogenesis, Vascular disorders

Hiroyuki Murota, Nagasaki University Graduate School of Biomedical Sciences, Department of Dermatology, Nagasaki, Japan
Sweat gland, Sweat, Itch, Pruritus, Atopic dermatitis

Yuuni Nakamura, Osaka University, Suita, Japan
Innate immunity and inflammation, Microbiology, Skin microbiome

Daisuke Namba, The University of Tokyo, Bunkyo-Ku, Japan
Keratinocytes, Stem cells, Regeneration

Sayaka Shibata, The University of Tokyo, Bunkyo-Ku, Japan
Keratinocytes, Psoriasis, Immune cells

Yutaka Shimomura, Yamaguchi University Hospital, Ube, Japan
Genetic skin disorders, Hair biology

Satoru Shinkuma, Nara Medical University, Kashihara, Japan
Genetic diseases, Regenerative therapy, Gene therapy, Gene analysis

Hideyuki Ujiiie, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Autoimmune blistering diseases, Atopic dermatitis, and adaptive immunity (especially regulatory T cells)

Rei Watanabe, Osaka University, Suita, Japan
Skin immunology, Skin T cells, Regulatory B cells, Psoriasis

Editorial Board

Jonathan Barker, London, United Kingdom
Tilo Biedermann, Tübingen, Germany
Andrew Blauvelt, Portland, United States of America
Leena Bruckner-Tuderman, Freiburg im Breisgau, Germany
Angela Christiano, New York, United States of America
Kevin Cooper, Cleveland, United States of America
David J Eedy, Craigavon, United Kingdom
Craig Elmets, Birmingham, United States of America
Gary Fisher, Ann Arbor, United States of America
Manabu Fujimoto, Suita, Japan

Hiroshi Shimizu, Sapporo, Japan
(2003 - 2008)
Akimichi Morita, Nagoya, Japan
(2008 - 2013)
Yoshiki Tokura, Hamamatsu, Japan
(2013 - 2018)
Riichiro Abe, Niigata, Japan
(2018-2023)

Section Editors

Yoshiihide Asano, Tohoku University, Sendai, Japan
Collagen disease (especially scleroderma), Fibrosis, Vasculopathy, Autoimmunity

Curdin Conrad, University of Lausanne, Lausanne, Switzerland
Chronic inflammatory skin diseases, with a focus on psoriasis, rosacea, etc., Targeted therapies and their side effects, including targeted synthetic DMARDS (such as JAK inhibitors, TYK2), Innate and adaptive immunity, focusing on pDCs, T cell subsets, and signature pathways (Th1, Th2, Th17)

Hironobu Fujiwara, Laboratory for Tissue Microenvironment, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan
Stem cell, Development, Regeneration, Extracellular matrix, Skin

Nikolas Haass, University of Queensland, Brisbane, Australia
Melanoma, Cancer Cell Biology, Targeted Therapy, Immune Therapy, Signalling Pathways, 3D Cell Culture, , Real-time Imaging

Tetsuya Honda, Hamamatsu University School of Medicine, Hamamatsu, Japan
Immunology, Inflammation, Atopic dermatitis, Psoriasis

Thomas Hornyak, University of Maryland Baltimore, Baltimore, United States of America
Immunology, Inflammation, Atopic dermatitis, Psoriasis

Ohsang Kwon, Seoul National University, Gwanak-gu, South Korea
Hair biology, Stem cell research, Wound healing, Regenerative medicine

Cheng-Che E. Lan, Kaohsiung Medical University, Kaohsiung, Taiwan
Photomedicine, Pigmentary disorders, Wound healing

Sei-ichiro Motegi, Gunma University, Maebashi, Japan
Systemic sclerosis, Skin fibrosis, Wound healing, Mesenchymal stem cells, Pressure ulcer, Angiogenesis, Vascular disorders

Hiroyuki Murota, Nagasaki University Graduate School of Biomedical Sciences, Department of Dermatology, Nagasaki, Japan
Sweat gland, Sweat, Itch, Pruritus, Atopic dermatitis

Yuuni Nakamura, Osaka University, Suita, Japan
Innate immunity and inflammation, Microbiology, Skin microbiome

Daisuke Namba, The University of Tokyo, Bunkyo-Ku, Japan
Keratinocytes, Stem cells, Regeneration

Sayaka Shibata, The University of Tokyo, Bunkyo-Ku, Japan
Keratinocytes, Psoriasis, Immune cells

Yutaka Shimomura, Yamaguchi University Hospital, Ube, Japan
Genetic skin disorders, Hair biology

Satoru Shinkuma, Nara Medical University, Kashihara, Japan
Genetic diseases, Regenerative therapy, Gene therapy, Gene analysis

Hideyuki Ujiiie, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Autoimmune blistering diseases, Atopic dermatitis, and adaptive immunity (especially regulatory T cells)

Rei Watanabe, Osaka University, Suita, Japan
Skin immunology, Skin T cells, Regulatory B cells, Psoriasis

Editorial Board

Jonathan Barker, London, United Kingdom
Tilo Biedermann, Tübingen, Germany
Andrew Blauvelt, Portland, United States of America
Leena Bruckner-Tuderman, Freiburg im Breisgau, Germany
Angela Christiano, New York, United States of America
Kevin Cooper, Cleveland, United States of America
David J Eedy, Craigavon, United Kingdom
Craig Elmets, Birmingham, United States of America
Gary Fisher, Ann Arbor, United States of America
Manabu Fujimoto, Suita, Japan
Keitarou Fukuda, Wako, Japan
Satoshi Fukushima, Kumamoto, Japan
Richard Gallo, La Jolla, United States of America
Stephan Grabbe, Mainz, Germany
Kathleen Green, Chicago, United States of America
Bernhard Homey, Düsseldorf, Germany
Masatoshi Jinnin, Wakayama, Japan
Sarolta Karpati, Budapest, Hungary
Akiharu Kubo, Kobe, Japan
Thomas Kupper, Boston, United States of America
Thomas Lugger, Münster, Germany
Mary Matsui, New York, New York, USA
Takeshi Matsui, Tokyo, Japan
John McGrath, London, United Kingdom
Robert Modlin, Los Angeles, United States of America
Ken Natsuga, Sapporo, Japan
Emi Nishimura, Tokyo, Japan
Manabu Ohyama, Tokyo, Japan
Naoko Okiyama, Tokyo, Japan
Vincent Piguet, Toronto, Canada
Nicholas Reynolds, Newcastle Upon Tyne, United Kingdom
Dennis Roop, Aurora, United States of America
Andre Rougier, Paris, France
Akiko Sada, Fukuoka Nishi Ward, Japan
Yayoi Tada, Tokyo, Japan
Hayato Takahashi, Tokyo, Japan
Takuya Takeichi, Nagoya, Japan
Erwin Tschachler, Wien, Austria
Daisuke Tsuruta, Osaka, Japan
Yang Wang, Beijing, China
Yukie Yamaguchi, Kanagawa, Japan
Jai-II Youn, Seoul, South Korea
Hsin-Su Yu, Kaohsiung, Taiwan
Giovanna Zambruno, Roma, Italy
Xue-Jun Zhang, Hefei, China
GUIDE FOR AUTHORS

INTRODUCTION

JDS is committed to publishing peer-reviewed dermatological research and reviews. In addition to basic skin research, clinical research is within the scope of JDS when it is informative and well-performed. For example, JDS accepts submission of extensive clinical trials and retrospective clinical studies. However, studies on simple clinical use of undefined or as yet uncharacterized material are out of the scope of our journal. Original articles (research papers), letters to the Editor and review articles are welcomed. All manuscripts must be typed in English and must not be in submission or have been or be published in any other journal. The entire manuscript text should be typed double spaced, including the abstract, footnotes, references, legends and tables, with 3-cm margins. Any changes should not be included in the manuscript file (as tracked changes).

Authors must submit the relevant submission checklist with their manuscript:

- Checklist for Letters to the Editor
- Checklist for Original Articles (Research Papers)
- Checklist for Review Articles


Type of Contribution

Original Articles (referred to as Research Papers)
Research papers should not exceed 3500 words, 6 figures including tables and contain no more than 50 references. A single figure or table can be made but should contain no more than 8 separate panels labelled from (a) to (h). Trade names must have an initial capital; the trivial name for a compound may be used if the formal, chemical name (as established by international convention) is given after the first use.

Basic and clinical scientific studies being submitted as a research paper should be organized as follows:  
- Title Page (including the name of the corresponding author and their e-mail address)
- Structured abstract (maximum of 250 words and should be divided into the following sections: Background, Objective, Methods, Results, and Conclusion)
- Introduction
- Materials and Methods
- Results
- Discussion
- Acknowledgements
- References(Maximum of 50)
- Legends
- Tables and Figures.

Letters to the Editor
These will report original data or may discuss published articles. With the following exceptions, submission requirements for Letters to the Editor are the same as for regular manuscripts. Letters must be less than 1000 words in length, and cannot include more than 10 references and two figures (including tables). A single Figure or Table can be made but should contain no more than 8 separate panels labeled from (a) to (h). One panel may be composed of multiple figures with annotation around individual panels to make viewing easier. An abstract and subheadings should not be included in Letters to the editor. Comments may be solicited from authors if the letter refers to a particular article in the journal. Letters that report original data will be reviewed. All letters to the Editor are subject to editing and possible abridgement. Letters to the Editor will be included in the Medline database.

Review Articles
A specific field is reviewed through classical and up-dated literature. Review articles should not exceed 3500 words from introduction to conclusion, 3 figures (including tables) and contain no more than 50 references, except in exceptional circumstances. A single Figure or Table can be made but should
contain no more than 8 separate panels labelled from (a) to (h). An abstract is required. Include in the review manuscript a short (maximum 100 words) biography of the first author, along with a passport-type photograph.

**Contact Details for Submission**
For inquiries about manuscripts please contact:

**JDS Editorial office**
Editor-in-Chief, Shigetoshi Sano
4-23-406 Hagoromo cho
Nishinomiya Hyogo
662-0051, Japan
E-mail: jds@jsid.org

**BEFORE YOU BEGIN**

**Ethics in publishing**
Please see our information on Ethics in publishing.

**Informed consent and patient details**
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

**Conflict of interest**
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also https://www.elsevier.com/conflictofinterest. All authors must sign either the JDS Conflict of Interest Disclosure, which can be downloaded from JDS Conflicts.pdf or a statement declaring that the authors do not have any relevant conflicts of interest, which can be downloaded from JDS No Author Conflicts.pdf.

**Declaration of generative AI in scientific writing**
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.
Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see https://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder. All authors must sign the JDS Author Declaration Form, which can be downloaded from: JDS Author declaration form.pdf.

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses
Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important
for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

**Author comments to the Editor**

Authors should enter their comments to the Editor on the ScholarOne website, including the following information: 1) The manuscript has not been submitted for publication elsewhere. 2) All authors have significantly contributed to the manuscript and all agree with its contents. 3) Authors do not have any relevant financial interests in the findings from this manuscript.

**Author contributions**

For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor’s specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; and Writing - review & editing. Note that not all roles may apply to every manuscript, and authors may have contributed through multiple roles. More details and an example.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Requirements for clinical research trials**

Human subject studies must have been approved by the authors' Institutional Review Board (IRB) or its equivalent. Authors will be asked to upload their IRB approval during the article submission process.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open access
Please visit our Open Access page for more information about open access publishing in this journal.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.

Microarray and RNA Sequencing Data
High throughput data (microarray and RNA sequencing data) should be deposited to the Gene Expression Omnibus (GEO) database at http://www.ncbi.nlm.nih.gov/geo/. Upon submission of manuscript, authors should supply their GEO accession numbers within the text of their manuscript (e.g., “GEO ID: GSE27196”). Upon publication, the ScienceDirect version of the article will automatically link to the relevant data.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
Please submit your article via https://mc.manuscriptcentral.com/jdermscience.

Suggesting reviewers
Please submit the names and institutional e-mail addresses of several potential reviewers.

You should not suggest reviewers who are colleagues, or who have co-authored or collaborated with you during the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Further, in order to provide a broad and balanced assessment of the work, and ensure scientific rigor, please suggest diverse candidate reviewers who are located in different countries/regions from the author group. Also consider other diversity attributes e.g. gender, race and ethnicity, career stage, etc. Finally, you should not include existing members of the journal's editorial team, of whom the journal are already aware.

Note: the editor decides whether or not to invite your suggested reviewers.

PREPARATION

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Article structure
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Structured abstract
A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Before approving the initial submission of your manuscript, please review the file size of the PDF created by the system. If the PDF is too large, Editors or reviewers may experience problems downloading it. Methods for reducing the size of the PDF include submitting lower-resolution versions of your figures for the initial submission or reducing the size of items such as the Conflict of Interest, Author Declaration, or Checklist.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. Further information on the preparation of electronic artwork.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.
Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Referencing

Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:

Reference to a journal publication with an article number:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a website:

Reference to a dataset:

Reference to software:

PLEASE NOTE: A maximum of six authors may be listed. In the case of more than six authors, please list 6 authors of your choosing and then et al.

Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Submission checklist
The relevant checklist from the list below must be submitted with your manuscript. for further specifics regarding the article type please consult the Guide for Authors.

Checklist for Letters to the Editor

Checklist for Original Articles (Research Papers)

Checklist for Review Articles

AFTER ACCEPTANCE

Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive 25 free paper offprints, or alternatively a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

Highlights
Highlights are mandatory for both full research and review articles as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).